Laurie M Gay

List of Publications by Year
in descending order

92 papers	4,418 citations	377584 21 h-index	129628 63 g-index
92 all docs	92 docs citations	92 times ranked	9212 citing authors

#	Article	IF	Citations
1	Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 367.e1-367.e5.	0.8	11
2	Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response. Oncologist, 2020, 25, e198-e202.	1.9	11
3	The Panâ€Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. Oncologist, 2020, 25, e39-e47.	1.9	13
4	Unique Genomic Landscape of High-Grade Neuroendocrine Cervical Carcinoma: Implications for Rethinking Current Treatment Paradigms. JCO Precision Oncology, 2020, 4, 972-987.	1.5	16
5	Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. European Urology, 2020, 77, 548-556.	0.9	41
6	Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors. European Urology Focus, 2019, 5, 748-755.	1.6	29
7	Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies. Gynecologic Oncology, 2019, 154, 199-206.	0.6	23
8	Genomic Features for Therapeutic Insights of Chemotherapy-Resistant, Primary Mediastinal Nonseminomatous Germ Cell Tumors and Comparison with Gonadal Counterpart. Oncologist, 2019, 24, e142-e145.	1.9	22
9	Genomic Landscape of Adult and Pediatric BCR-ABL1-Like B-Lymphoblastic Leukemia Using Parallel DNA and RNA Sequencing. Oncologist, 2019, 24, 372-374.	1.9	5
10	Comparative Genomic Profiling of Refractory and Metastatic Penile and Nonpenile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic Therapy. Journal of Urology, 2019, 201, 541-548.	0.2	57
11	Penile and uterine cervical squamous cell carcinomas: A comparative genomic profiling study.. Journal of Clinical Oncology, 2019, 37, 514-514.	0.8	2
12	Genomic features of metastatic testicular sex cord stromal tumors.. Journal of Clinical Oncology, 2019, 37, 532-532.	0.8	1
13	Anal melanoma: A comparative comprehensive genomic profiling study.. Journal of Clinical Oncology, 2019, 37, 551-551.	0.8	1
14	Ductal and acinar carcinomas of the prostate: A comparative comprehensive genomic profiling study.. Journal of Clinical Oncology, 2019, 37, 271-271.	0.8	0
15	Genomic findings in adenocarcinoma of the urinary bladder.. Journal of Clinical Oncology, 2019, 37, 132-132.	0.8	0
16	Malignant pheochromocytoma: A comprehensive genomic profiling study.. Journal of Clinical Oncology, 2019, 37, 508-508.	0.8	2
17	Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens. Blood, 2018, 131, 2501-2505.	0.6	57
18	Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer, 2018, 124, 1358-1373.	2.0	151

#	Article	IF	Citations
19	Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clinical Cancer Research, 2018, 24, 3282-3291.	3.2	44
20	BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy. Clinical Breast Cancer, 2018, 18, 184-188.	1.1	34
21	Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing. Oncologist, 2018, 23, 776-781.	1.9	8
22	BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent Alterations. JCO Precision Oncology, 2018, 2, 1-15.	1.5	24
23	Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies. JCO Precision Oncology, 2018, 2018, 1-14.	1.5	39
24	RET rearrangements are actionable alterations in breast cancer. Nature Communications, 2018, 9, 4821.	5.8	87
25	Precision Neuro-oncology: the Role of Genomic Testing in the Management of Adult and Pediatric Gliomas. Current Treatment Options in Oncology, 2018, 19, 41.	1.3	8
26	Primary pulmonary sarcomas (PSRC): A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2018, 36, 11553-11553.	0.8	1
27	PBRM1 mutation and immunotherapy efficacy: A comprehensive genomic profiling (CGP) assessment.. Journal of Clinical Oncology, 2018, 36, 12091-12091.	0.8	4
28	MSI-high and MSI-stable colorectal carcinomas (CRC): A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2018, 36, 3574-3574.	0.8	5
29	Comprehensive genomic characterization of chemotherapy-resistant testicular germ cell tumors (TGCT).. Journal of Clinical Oncology, 2018, 36, 4555-4555.	0.8	1
30	Genomic mutation profiles of paired ovarian cancers (OC) across time.. Journal of Clinical Oncology, 2018, 36, 5521-5521.	0.8	1
31	Assessment of activating estrogen receptor 1 (ESR1) mutations in gynecologic malignancies.. Journal of Clinical Oncology, 2018, 36, 5590-5590.	0.8	1
32	Comprehensive genomic profiling of anaplastic thyroid carcinoma.. Journal of Clinical Oncology, 2018, 36, 6089-6089.	0.8	5
33	PBRM1 genomic alterations in mesothelioma: Potential predictor of immunotherapy efficacy.. Journal of Clinical Oncology, 2018, 36, 8562-8562.	0.8	2
34	Genomic profiling of carcinomas of unknown primary (CUP) to support clinical decisions.. Journal of Clinical Oncology, 2018, 36, e24162-e24162.	0.8	6
35	Difference of genomic signatures and opportunities for targeted and immunotherapies in castrate resistant TMPRSS2:ERG fusion positive and TMPRSS2:ERG wild type refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC).. Journal of Clinical Oncology, 2018, 36, 348-348.	0.8	4
36	Refractory testicular pure seminoma (PS) and non-seminomatous(NS) germ cell tumors (GCT): A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2018, 36, 565-565.	0.8	1

#	Article	IF	Citations
37	Carcinomas of the renal medulla: A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2018, 36, 640-640.	0.8	0
38	Comparative genomic profiling (CGP) of refractory/metastatic penile (mPSCC) and non-penile cutaneous squamous cell carcinoma (mCSCC).. Journal of Clinical Oncology, 2018, 36, 552-552.	0.8	1
39	Choroid plexus tumors of the central nervous system: Searching for therapy targets with comprehensive genomic profiling.. Journal of Clinical Oncology, 2018, 36, e14084-e14084.	0.8	0
40	PD-L1 genomic alterations (GA) in solid tumors and hematologic malignancies: A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2018, 36, 12092-12092.	0.8	0
41	FGFR3 Driven Metastatic Urothelial Carcinoma of the Urinary Bladder (mUCB): A Comprehensive Genomic Profiling Study.. Journal of Clinical Oncology, 2018, 36, 4531-4531.	0.8	0
42	Carcinomas of the renal medulla: A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2018, 36, e16586-e16586.	0.8	0
43	Comprehensive genomic profiling of lung cancer cytologic specimens obtained by guided fine-needle aspirate biopsies.. Journal of Clinical Oncology, 2018, 36, e21002-e21002.	0.8	0
44	Comprehensive genomic profiling of metastatic cutaneous adnexal carcinomas to reveal multiple routes to targeted and immunotherapies.. Journal of Clinical Oncology, 2018, 36, 9587-9587.	0.8	1
45	Comprehensive genomic profiling of acral and mucosal melanomas to support clinical decision making.. Journal of Clinical Oncology, 2018, 36, e21629-e21629.	0.8	0
46	Primary sarcomas of the urinary bladder: A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2018, 36, e16530-e16530.	0.8	0
47	Differences in genomic signatures and opportunities for targeted and immunotherapy treatment between castrate-resistant TMPRSS2:ERG fusion-positive and -negative refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC).. Journal of Clinical Oncology, 2018, 36, 5061-5061.	0.8	0
48	Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra. Cancer Research, 2017, 77, 509-519.	0.4	75
49	Comprehensive genomic profiling of malignant phyllodes tumors of the breast. Breast Cancer Research and Treatment, 2017, 162, 597-602.	1.1	38
50	Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Medicine, 2017, 9, 34.	3.6	2,480
51	Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options. Gynecologic Oncology Reports, 2017, 20, 62-66.	0.3	19
52	Comprehensive genomic sequencing and the molecular profiles of clinically advanced breast cancer. Pathology, 2017, 49, 120-132.	0.3	18
53	ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy. Oncologist, 2017, 22, 1444-1450.	1.9	81
54	General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study. Human Pathology, 2017, 70, 84-91.	1.1	20

#	Article	IF	Citations
55	Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy. Cancer, 2017, 123, 3628-3637.	2.0	57
56	Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures. Oncologist, 2017, 22, 1478-1490.	1.9	176
57	BRCA1 reversion mutation acquired after treatment identified by liquid biopsy. Gynecologic Oncology Reports, 2017, 21, 57-60.	0.3	24
58	Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer. Gynecologic Oncology Reports, 2017, 21, 78-80.	0.3	18
59	Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options. Oncologist, 2017, 22, 834-842.	1.9	37
60	Comprehensive Genomic Profiling of Central Giant Cell Lesions Identifies Clinically Relevant Genomic Alterations. Journal of Oral and Maxillofacial Surgery, 2017, 75, 955-961.	0.5	7
61	BRAF: An emerging target for triple-negative breast cancer.. Journal of Clinical Oncology, 2017, 35, 1099-1099.	0.8	7
62	Genomic profiling of squamous malignancies across anatomic sites.. Journal of Clinical Oncology, 2017, 35, 11512-11512.	0.8	2
63	A clinical and genomic profile of inflammatory myofibroblastic tumors.. Journal of Clinical Oncology, 2017, 35, 1538-1538.	0.8	4
64	Mutational burden of tumors with primary site unknown.. Journal of Clinical Oncology, 2017, 35, 3039-3039.	0.8	6
65	Targeted therapy for HER2 driven colorectal cancer.. Journal of Clinical Oncology, 2017, 35, 3583-3583.	0.8	3
66	Precision medicine for gallbladder cancer using somatic copy number amplifications (SCNA) and DNA repair pathway gene alterations.. Journal of Clinical Oncology, 2017, 35, 4076-4076.	0.8	8
67	Comprehensive genomic profiling (CGP) with loss of heterozygosity (LOH) to identify therapeutically relevant subsets of ovarian cancer (OC).. Journal of Clinical Oncology, 2017, 35, 5512-5512.	0.8	10
68	BRCA1/2 reversion mutations revealed in breast and gynecologic cancers sequenced during routine clinical care using tissue or liquid biopsy.. Journal of Clinical Oncology, 2017, 35, 5551-5551.	0.8	2
69	BRAF fusions in clinically advanced non-small cell lung cancer: An emerging target for anti-BRAF therapies.. Journal of Clinical Oncology, 2017, 35, 9072-9072.	0.8	11
70	Landscape of genomic alterations (GA) and tumor mutational burden (TMB) in different metastatic melanoma (MM) subtypes.. Journal of Clinical Oncology, 2017, 35, 9536-9536.	0.8	18
71	Characteristics of advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving molecular diagnostic (MD) testing in U.S. routine clinical practice.. Journal of Clinical Oncology, 2017, 35, e20627-e20627.	0.8	2
72	Comprehensive genomic profiling of relapsed and refractory small cell neuroendocrine carcinoma of the urinary bladder.. Journal of Clinical Oncology, 2017, 35, 350-350.	0.8	3

#	Article	IF	Citations
73	Comprehensive genomic profiling of urethral cancer to reveal distinctive features compared to bladder cancer.. Journal of Clinical Oncology, 2017, 35, 429-429.	0.8	0
74	Impact of age on genomic alterations associated with pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2017, 35, 282-282.	0.8	0
75	Association of tumor mutational burden in cutaneous squamous cell carcinoma with genomic alterations in Notch family receptors.. Journal of Clinical Oncology, 2017, 35, e13031-e13031.	0.8	0
76	Occurrence of ALK fusions in cancers other than non-small cell lung cancer in a wide variety of tumor types and response to anti-ALK targeted therapy.. Journal of Clinical Oncology, 2017, 35, 11595-11595.	0.8	1
77	BRCA1/2 reversion mutations in pancreatobiliary cancer identified from patient biopsies.. Journal of Clinical Oncology, 2017, 35, 4130-4130.	0.8	0
78	FoundationOne as a relevant tool for comprehensive genomic profiling and assessment of tumor mutation burden in the era of precision oncology in India.. Journal of Clinical Oncology, 2017, 35, e23096-e23096.	0.8	0
79	Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with metastatic breast cancer (mBC).. Journal of Clinical Oncology, 2017, 35, 1016-1016.	0.8	1
80	BRCA1/2 reversion mutations in prostate cancer identified from clinical tissue and liquid biopsy samples.. Journal of Clinical Oncology, 2017, 35, 5024-5024.	0.8	1
81	Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for antiâ€HER2 targeted therapies. Cancer, 2016, 122, 2654-2662.	2.0	71
82	Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials. Oncologist, 2016, 21, 684-691.	1.9	85
83	The distribution of <scp>BRAF</scp> gene fusions in solid tumors and response to targeted therapy. International Journal of Cancer, 2016, 138, 881-890.	2.3	248
84	Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study. Breast Cancer Research and Treatment, 2016, 155, 405-413.	1.1	17
85	Comprehensive genomic profiling of neuroendocrine carcinoma of the prostate.. Journal of Clinical Oncology, 2016, 34, 5027-5027.	0.8	3
86	Deep sequencing of metastatic cutaneous basal cell and squamous cell carcinomas to reveal distinctive genomic profiles and new routes to targeted therapies.. Journal of Clinical Oncology, 2016, 34, 9522-9522.	0.8	3
87	Analysis of tumor mutation burden (TMB) in >51,000 clinical cancer patients to identify novel non-coding PMS2 promoter mutations associated with increased TMB.. Journal of Clinical Oncology, 2016, 34, 9572-9572.	0.8	5
88	Distinguishing head and neck cancer metastasis from second primary squamous lung cancer in the genomic era.. Journal of Clinical Oncology, 2016, 34, e17506-e17506.	0.8	1
89	Biomarkers of immune checkpoint inhibitor response in metastatic breast cancer: PD-L1 protein expression, CD274 gene amplification, and total mutational burden.. Journal of Clinical Oncology, 2016, 34, 3057-3057.	0.8	2
90	Immunotherapy (IO) versus targeted therapy triage in endometrial adenocarcinoma (EA) by concurrent assessment of tumor mutation burden (TMB), microsatellite instability (MSI) status, and targetable genomic alterations (GA).. Journal of Clinical Oncology, 2016, 34, 5591-5591.	0.8	2

#	Article	IF	Citations
91	A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma. Clinical Cancer Research, 2014, 20, 68-75.	3.2	120
92	A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib. Case Reports in Oncology, 2014, 7, 628-632.	0.3	13